Table 1

Treatment information

PatientRoute of biopsyPrimary treatmentSecondary treatment (where applicable)Reasons for secondary treatmentTime between biopsy and enucleation/endoresection (days)
1TS—FNABRu106-RTEnucleationTumour recurrence277
2TRRu106-RT*EndoresectionTumour recurrence357
3TREnucleation3
4TREnucleation45
5TREnucleation11
6TREnucleation14
7TREnucleation31
8TRRu106-RTEnucleationTumour recurrence213
9TREnucleation31
10TREnucleation14
11TREnucleation3
12TRRanibizumab†EnucleationTumour progression91
13TRRanibizumab†EnucleationTumour progression38
14TRRanibizumab†EnucleationPatient request after 2nd injection52
15TREnucleation17
16TRRanibizumab †EnucleationTumour progression49
17TRRanibizumab†EnucleationTumour progression56
18TRPBRT*EndoresectionToxic tumour syndrome49
19TRRanibizumab†EnucleationNo tumour regression; end of trial192
20TRRanibizumab†EnucleationTumour progression156
21TS—scleral flapRu106-RTEnucleationTumour recurrence1141
22TREndoresection21
23TRRu106-RTEnucleationTumour recurrence2422
24TRPBRT*EnucleationTumour recurrence479
25TRPBRT*EnucleationTumour recurrence231
26TS—FNABEnucleation14
27TRPBRT*EnucleationTumour recurrence1029
28TREnucleation14
  • *Biopsy taken shortly after radiotherapy.

  • †Ranibizumab was used as a primary treatment only within the phase II NITRO Trial ISRCTN35236442.

  • FNAB, fine needle aspiration biopsy; PBRT, proton beam radiotherapy; Ru106-RT, plaque radiotherapy; TR, transretinal; TS, transscleral.